Kura Oncology Gets 330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin
SNDX Stock | USD 13.09 0.22 1.65% |
Slightly above 55% of Syndax Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Syndax Pharmaceuticals suggests that many traders are impartial. Syndax Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Syndax Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Syndax |
Kura Oncology already had a broad development plan for ziftomenib in leukemias, but the agreement with Kyowa Kirin provides the cash to execute it and a partner to commercialize the drug globally. Ziftomenib is in the same class of medicines as Syndax Pharmaceuticals Revuforj, which won FDA approval last week.
Read at medcitynews.com
Syndax Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Syndax Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Syndax Pharmaceuticals Fundamental Analysis
We analyze Syndax Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syndax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syndax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Syndax Pharmaceuticals is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Syndax Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Syndax Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Syndax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Syndax Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Syndax Pharmaceuticals Related Equities
MRSN | Mersana Therapeutics | 5.88 | ||||
KALV | Kalvista Pharmaceuticals | 4.90 | ||||
MLYS | Mineralys Therapeutics, | 3.73 | ||||
CGEM | Cullinan Oncology | 3.37 | ||||
STRO | Sutro Biopharma | 3.21 | ||||
AVTE | Aerovate Therapeutics | 1.56 | ||||
VRDN | Viridian Therapeutics | 1.47 | ||||
COGT | Cogent Biosciences | 1.29 | ||||
MRUS | Merus BV | 1.24 | ||||
PLRX | Pliant Therapeutics | 1.12 | ||||
RVMD | Revolution Medicines | 0.75 | ||||
REPL | Replimune | 0.08 | ||||
DYN | Dyne Therapeutics | 0.08 | ||||
CYTK | Cytokinetics | 0.70 | ||||
PCVX | Vaxcyte | 1.41 | ||||
KROS | Keros Therapeutics | 2.22 | ||||
INZY | Inozyme Pharma | 2.66 | ||||
EWTX | Edgewise Therapeutics | 3.77 | ||||
LRMR | Larimar Therapeutics | 4.04 |
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.